Jørstad H T, Boekholdt S M, Wareham N J, Khaw K T, Peters R J G
Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.
Neth Heart J. 2017 Mar;25(3):173-180. doi: 10.1007/s12471-016-0927-2.
Dutch cardiovascular disease (CVD) prevention guidelines recommend the use of modified SCORE risk charts to estimate 10-year risk of fatal and nonfatal CVD (myocardial infarction, cerebrovascular disease and congestive heart failure). This combined risk is derived from the SCORE mortality risk using multipliers. These multipliers have been shown to underestimate overall CVD risk. We aimed to compare the current Dutch risk charts with charts that estimate a broader range of clinically relevant CVD using updated multipliers.
We constructed new risk charts for 10-year CVD using updated, recently published multipliers from the EPIC-Norfolk study, based on ratios of fatal CVD to clinically relevant CVD (fatal plus nonfatal CVD requiring hospitalisation for ischaemic heart disease, cardiac failure, cerebrovascular disease, peripheral artery disease, and aortic aneurysm). Our primary outcome was the proportion of the three risk categories, i. e. 'high risk' (>20% 10-year risk), 'intermediate risk' (10-19%) and 'low risk' (<10%) in the new risk charts as compared with the current risk charts.
Applying the updated fatal CVD/clinical CVD multipliers led to a marked increase in the high-risk categories (109 (27%) vs. 244 (61%), (p < 0.001)), an absolute increase of 229%. Similarly, the number of low-risk categories decreased (190 (48%) vs. 81 (20%) (p < 0.001)).
The current Dutch risk charts seriously underestimate the risk of clinical CVD, even in the first 10 years. Even when analyses are restricted to CVD events that required hospitalisation, true 10-year risks are more than double the currently estimated risks. Future guidelines may be revised to reflect these findings.
荷兰心血管疾病(CVD)预防指南建议使用改良的SCORE风险图表来估计致命和非致命性CVD(心肌梗死、脑血管疾病和充血性心力衰竭)的10年风险。这种综合风险是通过使用乘数从SCORE死亡率风险中得出的。这些乘数已被证明会低估总体CVD风险。我们旨在将当前的荷兰风险图表与使用更新后的乘数来估计更广泛的临床相关CVD范围的图表进行比较。
我们使用来自EPIC-诺福克研究的最新公布的乘数构建了10年CVD的新风险图表,该乘数基于致命性CVD与临床相关CVD(致命性加因缺血性心脏病、心力衰竭、脑血管疾病、外周动脉疾病和主动脉瘤需要住院治疗的非致命性CVD)的比率。我们的主要结局是新风险图表中与当前风险图表相比的三个风险类别,即“高风险”(10年风险>20%)、“中风险”(10 - 19%)和“低风险”(<10%)的比例。
应用更新后的致命性CVD/临床CVD乘数导致高风险类别显著增加(109例(27%)对244例(61%),(p<0.001)),绝对增加了229%。同样,低风险类别的数量减少(190例(48%)对81例(20%)(p<0.001))。
当前的荷兰风险图表严重低估了临床CVD的风险,即使在前10年也是如此。即使分析仅限于需要住院治疗的CVD事件,真实的10年风险也比目前估计的风险高出一倍多。未来的指南可能会进行修订以反映这些发现。